All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Alice Mims, Ohio State University Comprehensive Cancer Center - The James, Columbus, US. We asked, How can outcomes be improved in patients with molecularly-defined high-risk acute myeloid leukemia (AML)?
How can outcomes be improved in patients with molecularly-defined high-risk AML?
Mims outlines the use of the 2022 European LeukemiaNet risk classification in molecularly defining high-risk AML and discusses the importance of cytogenetics and sequencing at the time of diagnosis to guide treatment decisions and determine eligibility for clinical trials. Mims goes on to discuss data presented at ASH on patients with TP53 mutations, FLT3-ITD, and KMT2A rearrangements treated with therapeutics including azacitidine, venetoclax, magrolimab, eprenetapopt (APR-246), gilteritinib, and revumenib (SNDX-5613).
Editorial theme | Navigating the latest updates in classification systems for AML: The 2022 ELN recommendations
During the EHA 2023, Hartmut Döhner and Gert Ossenkoppele discussed the latest updates to the ELN 2022 recommendations and classification...
2022 ELN recommendations for the diagnosis of AML in adults
Major advances in the classification of AML, genomic diagnostics, and molecular markers of disease, the ELN has recently released a 2022 update, which includes revised genetic risk...
Subscribe to get the best content related to AML delivered to your inbox